We’re #hiring! Know anyone who might be interested?
About us
A Novel Biomarker Discovery Solution for Personalized Drug Development Denovo Biopharma is a private San Diego based biotech company, also operating in China, providing a novel biomarker solution to personalize drug development. The core technology of the company is its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effects. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in targeted patient population to achieve higher efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in most therapeutic areas, such as oncology and neurological diseases.
- Website
-
http://www.denovobiopharma.com
External link for Denovo Biopharma
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
- Founded
- 2011
- Specialties
- biomarker, biotechnology, drug development, late-stage, clinical trial, China, Oncology, and CNS
Locations
-
Primary
Get directions
10240 Science Center Dr
San Diego, California 92121, US
Employees at Denovo Biopharma
Updates
-
We are excited to share the news about the positive results from our late-stage trial in TRD!
I am pleased to share the positive results from our Phase 2b trial in treatment-resistant depression (TRD), which potentially represents the first genetic biomarker-guided treatment for any CNS disorder: https://lnkd.in/gNZQzYHC
Denovo Biopharma Announces a Major Breakthrough in Treatment-Resistant Depression with Precision Medicine
prnewswire.com